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Abstract.  Thrombospondin (TS)  is a modular adhe- 
sive glycoprotein that contains three domains previ- 
ously implicated in the attachment of cells to "IS. 
These include the amino-terminal  heparin-binding  do- 
main,  the carboxy terminal  cell or platelet-binding do- 
main,  and an RGDA sequence of TS.  We have charac- 
terized a mAb against human TS,  designated A4.1, 
which inhibits the attachment of human melanoma 
cells (G361) to TS.  The epitope for A4.1  lies within 
the amino terminal half of the central  stalklike region 
of "IS which is distinct from the three known cell at- 
tachment sites.  This region of TS is recovered in a 50- 
kD peptide after chymotryptic digestion of "IS in 
EDTA.  It contains the procollagen-like domain of TS 
as well as three type I repeats of a 60-residue segment 
homologous to two malarial  proteins and the comple- 
ment proteins properdin,  and factors C6 through C9. 
The purified chymotryptic fragment is an effective at- 
tachment factor for G361  cells. A4.1  blocks adhesion 
to the 50-kD domain, as do some sulfated glycocon- 
jugates. RGD (and RGE) peptides and mAbs against 
other domains of TS are not inhibitory.  Peptides (19 
mers) based on the core homology sequence of the 
three type I repeats of TS are potent attachment fac- 
tors for these cells, and this adhesion is also inhibited 
by sulfated glycoconjugates. A  polyclonal antibody 
raised against one of these peptides inhibits adhesion 
of G361  cells to the peptides,  to the 50-kD fragment 
and to intact "IS. Thus a new cell-adhesion site has 
been identified in TS whose sequence is very similar 
to the site identified in region II of the circum- 
sporozoite protein of malaria parasites (Rich, K. A., 
E  W.  George IV, J.  L.  Law,  and W. J.  Martin. 
1990.  Science (Wash. DC) 249:1574-1577.  Thus 
there may be a common receptor which binds TS, ma- 
larial proteins,  and properdin. 
T 
HROMBOSPONDIN (TS) 1 is a multidomain,  adhesive 
glycoprotein  that  functions  in  the  attachment,  mi- 
gration,  and proliferation  of a number of cell types 
(Frazier,  1987). It appears early in embryogenesis (O'Shea 
and Dixit,  1988; O'Shea et al., 1990) and its expression is 
transient and tightly regulated both in vivo and in vitro (Ma- 
jack et al., 1985, 1987). TS has a role in platelet aggregation 
(Dixit et al.,  1985b),  and is thought to be involved in the 
regulation  of smooth muscle cell growth by platelet-derived 
growth factor (Majack et al., 1985, 1988) a scenario which 
has implications  for atherogenesis.  "IS has been implicated 
in tumor cell metastasis (Tuszynski et al., 1987) and is syn- 
thesized by a number of highly metastatic and invasive tu- 
mors (Varani et ai., 1989). Most recently, TS and a hamster 
homologue of TS called gpl40 (Rastinejad et al., 1989) have 
been found to be potent inhibitors of endothelial  cell migra- 
tion  and  proliferation  stimulated  by angiogenic  mitogens 
(Good et al.,  1990;  Taraboletti  et al.,  1990).  The in vivo 
correlate of this activity is the inhibition  of angiogenesis  by 
TS and gpl40 in three different assays (Good et al.,  1990). 
These findings suggest that TS may have important roles in 
1.  Abbreviations  used in  this paper:  pAb,  polyclonal  antibody; TRAP, 
thrombospondin r~lated anonymous protein; "iS, thrombospondin. 
processes  such as  vascular development,  wound  healing, 
placental development,  and tumor growth. 
A first step in understanding  the molecular basis of TS ac- 
tion on cells is to define the ways in which cells can interact 
with this structurally  and functionally  complex protein.  As 
with other adhesive glycoproteins,  TS has multiple sites that 
bind to distinct  cellular receptors.  For example,  the NH2- 
terminal  heparin-binding  domain of TS has been identified 
as mediating  the binding  and internalization  of TS by en- 
dothelial  (Murphy-UUrich  and  Mosher,  1987)  and  CHO 
cells (Murphy-Ullrich  et al.,  1988). Further,  the spreading 
of cells on intact TS is blocked by soluble heparin  and by 
A2.5 (Roberts et al., 1987), a mAb specific for the heparin- 
binding  domain (Dixit et al.,  1985a).  A cell surface pro- 
teoglycan  of Mr 70000 has been identified  that appears  to 
act as a receptor for this region ofTS (Kaesberg et al., 1989; 
Sun  et al.,  1989).  The  COOH-terminal  platelet-  or cell- 
binding domain was thus named because of the inhibition of 
platelet aggregation (Dixit et ai., 1985b) and cell attachment 
(Roberts et al.,  1987) to TS by mAb C6.7 directed against 
the  COOH-terminal  18-kD  fragment  of the  180-kD  TS 
subunit (Galvin et al., 1985). This mAb is a potent inhibitor 
of the attachment of human melanoma cells such as G361, 
C32, and many other malignant  cells to "IS-coated plastic 
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tor with which this region of TS  interacts is  not clearly 
identified. Early reports indicated that the OKM5 antigen, 
now called CD36 and thought to be identical to platelet gplV 
(or gpmb), is a receptor for TS whose binding is blocked 
by mAb C6.7 (Asch et al.,  1987).  However,  recent experi- 
ments in which CD36 was cloned and expressed do not sup- 
port the idea that it binds TS (Oquendo et al., 1989).  RGD- 
containing peptides partially block the adhesion of smooth 
muscle, endothelial, normal rat kidney, U937 (Lawler et al., 
1988),  and C32 cells (Tuszynski et al., 1989) to TS-coated 
wells, suggesting that the RGDAC sequence near the COOH- 
terminal end of the calcium-binding domain of TS can also 
act as a cell attachment site. We have found partial inhibition 
of G361 melanoma cell attachment to "IS with RGD peptides 
(D. Jaye, and W. A. Frazier, manuscript in preparation) sug- 
gesting that these coils can also adhere to TS via an integrin- 
type receptor. 
In this report we present evidence that a fourth region of 
TS can act as a cell attachment site. We show that mAb A4.1 
which binds to the central chymotryptic fragment of the TS 
subunit inhibits TS-mediated cell attachment as well as mAb 
C6.7. Since this TS fragment does not contain any of the 
previously identified cell attachment sites of "IS described 
above,  we wanted to determine if mAb A4.1 was acting by 
indirectly hindering a known cell attachment site or sites or 
by blocking an as yet unknown site in the central stalk region 
of TS. To do this, a proteolytic fragment of TS containing 
the epitope for mAb A4.1 was purified and found to support 
the attachment of melanoma cells. We have identified a pep- 
tide sequence which is active in cell attachment that lies 
within the type I threefold repeats that are homologous to 
region II of malaria circumsporozoite (CS) proteins, throm- 
bospondin-related anonymous protein (TRAP), and the hu- 
man complement protein properdin. 
Materials and Methods 
Materials 
mAbs were raised as previously described by fusion of mouse spleen cells 
with the myeloma Sp2/Agl4 (Dixit et al., 1985b). mAbs were purified from 
mouse ascites fluid by chromatography on protein A-Sepharose  columns, 
elution being accomplished with the mildest acid conditions possible as de- 
termined for each antibody.  Specificity  of mAb A4.1 was established by 
Western blotting against samples of whole piatelets,  serum, and purified 
proteins.  G361  cells were obtained from the ATCC (#1424) and cultured 
in RPMI 1640 medium supplemented with 10% FCS at 5% CO2 (Roberts 
et ai.,  1987). Cells were passaged  by mild trypsin treatment. All proteins 
and reagents were obtained from Sigma Chemical Co. (St. Louis, MO) un- 
less otherwise specified. Dextran sulfates were from Pharmacia Fine Chem- 
icals (Uppsala, Sweden),  Mr 500,000;  ICN Radiocbemicals  (Irvine, CA) 
Mr 40,000 and Sigma Chemical Co. Mr 5,000. The peptides GRGDSP and 
GRGESP were from Immuno-Dynamics, Inc.  (San Diego,  CA).  Human 
plasma fibronectin  was the gift of 1". Broekelmann and Dr. J. A. McDonald. 
Human platelet "IS was purified as described (Dixit et ai., 1984) and human 
platelet factor 4 (PF4) was obtained from the same preparations by elution 
of the baparin-Sepbarose column with 2 M NaCI. 
Cell Adhesion Assay and Photography 
Cells were harvested from near confluent cultures by brief treatment with 
EDTA and were immediately washed and resuspended  in Hopes-buffered 
saline plus 4  mg/mi BSA.  A  100-#1 volume of this cell suspension was 
added to wells containing an equal volume of TBS (pH 7.6) with 2 mM each 
CaCI2 and MgC12. Cell viability was tested by trypan blue exclusion  and 
was  routinely  >90%.  Plastic 96-well  plates (lmmtmo Plate Maxisorp; 
Nunc, Roskilde,  Denmark) were coated with indicated substrate proteins 
by incubation in 50 #1 of TBS per well at the indicated concentrations over- 
night at 4°C or for 2 h at 370C. Wells were rinsed with TBS and blocked 
with 10 mg/rul BSA for 30 rain at room temperature.  After rinsing the 
plates, any inhibitors or other additions were made in 100 #1TBS and ceils 
added as above. Plates were incubated at 37°C for 1-2 h, rinsed three times 
with TBS, observed under Hoffman optics for qualitative assessment, and 
then rinsed three times with TBS. Adherent cells were photographed with 
a 40× Hoffman objective using Tri-X pan 400 ASA. Cell attachment was 
quantified with a coiorimetric react/on using endogenous cellular phospha- 
tase activity by adding  100 #1 of the following substrate/lysis  solution to 
each well:  1% Triton X-100, 6 mg/ml p-nitropbenylphosphate, in 50 mM 
sodium acetate buffer, pH 5.0. Wells were incubated for 1-2 h at 370C, the 
reaction stopped by the addition of 50 #1 1 N NaOH, and read in an ELISA 
plate reader (Dynatech Laboratories, Inc., Cambridge, MA) with a 410-nM 
filter. Wells were set up in triplicate and all experiments were repeated at 
least three times. Percent of cell attachment was determined by comparison 
of color yield with that obtained from the number of cells initially plated 
in each well.  Standard curves were  linear with cell number from 100- 
100,000 cells. 
Generation and Purification of 70- and 
25-kD Domains 
Proteolysis  of  human  piatelet  "IS  was  performed  with  TLCK-treated 
chymotrypsin at 1% (wt/wt) of TS in TBS, pH 7.4, 10 mM EIYI'A for 30-60 
min at room temperature as described (Gaivin et al.,  1985; Dixit et ai., 
1986).  "IS fragments were purified by gel filtration on Sephacryl  S-200 
columns and heparin-Sepbarose affinity chromatography to remove intact 
TS and purify the beparin-binding domain of "IS (Dixit et al.,  1984). The 
digests and purified fragments  were characterized by silver-stained  SDS- 
PAGE, and by Western blotfingtwith the panel of anti-TS mAbs. Purified 
fragments were free of intact TS, or fragments >70 kD on reducing SDS- 
PAGE (see Fig. 2).  The 70/50-kD fragments were trimeric on unreduced 
SDS-PAGE. 
Peptide Synthesis 
Peptides  based  on  "IS  amino  acid  sequences  were  synthesized  by the 
Washington University Protein Chemistry Facility (Mark Frazier, technical 
director) using a solid phase peptide synthesizer (model 380A; Applied Bio- 
systems,  Foster City, CA).  Peptides  were cleaved and deblocked  by Im- 
munodynamics, Inc.  and purified by reverse phase HPLC (Waters) using 
acetonitrile/0.1%  TFA solvent systems.  Purity was tested with analytical 
HPLC and peptides  were checked by amino acid composition and auto- 
mated sequence analysis (model 477A sequencer; Applied Biosystems). In- 
tegrity of tryptophan residues was analyzed by scanning UV spectroscopy. 
Peptides  were labeled with 12SI-Bolton  Hunter reagent (ICN Radiochemi- 
cais) by incubation of 40 nmol of peptide with 0.25 mCi of reagent in 0.1 M 
phosphate buffer, pH 7.4 for 2 h at room temperature.  Labeled peptides were 
purified  on G25 columns equilibrated in TBS and used to quantify  the 
amount of peptide immobilized on the plastic wells. 
Generation of Polyclonai Antibodies against Peptide H 
The cysteine-containing  version of peptide H (see Fig. 9 for sequence) was 
oxidized to form large polymeric aggregates (as judged by HPLC and gel 
filtration).  The dialyzed  and lyophilized  material was suspended  in water 
and complete Freund's adjuvant.  1 rag of peptide was injected subcutane- 
ously at 10 sites (100-#g each) on the backs of two white New Zealand fe- 
male rabbits. Each rabbit was subsequently boosted with 300/tg of peptide 
material three times, and exsanguinated.  Defibrinated,  cell-free serum was 
then purified on a protein A-Sepbarose  column 0Bio Pad Labbra~0ries, 
Richmond, CA) to obtain the IgG fraction. Reactivity of the IgG fraction 
was determined by ELISA against peptides I, II, and HI, and by Western 
blotting against TS and its chymotryptic  digest. 
Results 
Characterization and Mapping of mAb A4.1 
mAb A4.1  was selected by ELISA screening from hybrid- 
omas resulting from immunization with denatured "IS. Screen- 
The Journal of Cell Biology, Volume i 12,  1991  1032 Figure 1. Schematic representation of  the chymotryptic digestion of TS. In 1 mM calcium, the main products are the 25 kD, heparin-binding 
domain (region B), and the  120- and 20-kD fragments. Region C contains the cysteines forming interchaln disulfides; region D is the 
procoUagen-like segment; region E contains three type I repeats (see text); region F consists of three EGF-like repeats (type 1I); region 
G is the primary calcium-binding domain and is highly repetitive (type III repeats); region H is the platelet-(or cell-) binding domain. 
The single disulfides in region B and H are indicated as is the single free SH of "IS in region H, and the RGDA sequence in region (3. 
Above the figure are indicated the approximate locations of epitopes for mAbs. In EDTA, the digest progresses as indicated with essentially 
stepwise proteolysis from the COOH terminus. 
ing of positives on Western blots of TS digested with chymo- 
trypsin in the presence of  EDTA indicated that it reacted with 
the 70-kD fragment of TS which we and others have previ- 
ously characterized as containing the central stalk like region 
of "IS (Fig.  1).  This fragment begins with residue number 
241  of the mature "IS subunit and extends in a COOH-ter- 
minal direction to a site in or near the last of the three EGF- 
like repeats of TS (Galvin et al.,  1985). It includes the two 
cysteines at 252 and 256 which are responsible for trimer 
formation, hence the fragment migrates as a 210-kD species 
on nonreducing SDS gels and is visualized as a trimer with 
rotary shadowing EM (Galvin et al.,  1987). This fragment 
has been shown to contain the binding sites for collagens 
(Mumby et al.,  1984;  Galvin et al.,  1987),  plasminogen, 
fibronectin, laminin, and fibrinogen (Lawler et al.,  1986). 
Binding of A4.1 to EDTA-treated "IS is about twofold greater 
than to Ca  2÷ replete "IS, indicating that its epitope lies in a 
region that  is  somewhat Ca  :÷  sensitive.  Chymotryptic di- 
gestion of  TS proceeds in a stepwise manner from the COOH 
terminus as shown in Fig. 1. We have previously mapped an- 
other mAb designated Ati.1 as binding near the COOI-I-ter- 
minal end of the 70-kD fragment and whose binding to TS 
is  strongly inhibited by calcium (Dixit et al.,  1986).  We 
tested mAbs A4.1 and A6.1 for mutual competition in their 
binding to TS and found none, suggesting that their epitopes 
are quite far apart.  Hence, A4.1  probably binds  near the 
NH2 terminus of the 70-kD species.  As  shown in Fig.  1, 
further digestion of the 70-kD species occurs with prolonged 
chymotrypsin treatment  giving  rise  to  a  50-kD  fragment 
which is still trimeric on nonreducing SDS gels (not shown) 
indicating further digestion from the COOH terminus. A4.1 
binds to both the 50- and 70-kD fragments (Fig.  2) while 
A6.1 binds only to the 70-kD band proving that the A4.1 epi- 
tope is indeed NH2 terminal to that for A6.1. 
Effect of mAbs on Attachment of G361 Melanoma 
CeUs to TS 
As reported by Roberts et al. (1987), human melanomas such 
as G361 adhere to TS-coated plastic wells. We examined the 
effect of A4.1 on adhesion of these cells to TS. These results 
along with those of other mAbs for comparison are shown 
in Fig. 3. As reported previously (Roberts et al., 1987), mAb 
C6.7 has a dramatic inhibitory effect  on the adhesion of  G361 
cells  to  TS  (coated  at  50  #g/ml)  while  A2.5  (the  anti- 
heparin-binding domain monoclonal) has little effect on cell 
adhesion, mAb A4.1  is as potent as C6.7  at inhibiting cell 
adhesion in this assay, mAb A6.1 whose epitope lies between 
those of C6.7 and A4.1 (Fig. 1), shows only a slight effect on 
cell adhesion. We have made mAb A4.1  available to other 
laboratories and it has been reported that adhesion of rat 
smooth muscle cells (Majack et al., 1988), human keratino- 
cytes, and squamous carcinoma cells (Varani et al.,  1988) 
to "IS is  inhibited by A4.1.  Since C6.7  inhibits  secretion- 
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silver-stained SDS-PAGE (reduced) of purified 70/50 kD (lane 1) 
and 25 kD (lane 2) fragments of TS. Western blots of the 70/50 led 
shown in lane 1 were probed with mAb A4.1 (lane 3), mAb A6.1 
(lane 4). Lane 5 shows the Western blot of 70/50 kD probed with 
polyclonal antibody raised against peptide II. The 70/50-kD sample 
used for the blot in lane 5 had been treated with chymotrypsin for 
a longer period of time resulting in an increase in the ratio of the 
50- to 70-kD bands. 
dependent or secondary-phase platelet aggregation (Dixit et 
al., 1985b) we tested A4.1 in a platelet aggregation assay and 
found no effect on the aggregation of washed platelets stimu- 
lated with thrombin (not shown). 
jor  cell  attachment  site  exists  in  this  region of "IS. The 
purified fragments were also tested for contamination by 
other fragments using silver-stained SDS gels and Western 
blotting with mAbs. In particular, no contamination of the 
70/50-kD fragment by intact "IS or its larger digestion prod- 
ucts was seen (Fig.  2). 
While the 70/50-kD fragment of TS is active in the attach- 
ment of cells, it is not able to support their cytoskeletal rear- 
rangement or spreading. In many experiments, essentially no 
cell spreading was observed (Fig. 4 B). Roberts et ai. (1987) 
reported that the NH~-terminal heparin-binding domain of 
"IS is needed for spreading of G361 cells on "IS (Fig. 4 A). 
Interestingly, the purified beparin-binding domain alone is 
not a very potent attachment factor for these cells and the 
ceils that do attach do not spread (Fig. 4  C). In an attempt 
to reconstruct a fully functional "molecule" immobilized on 
plastic,  we mixed the 70/50-kD  fragment of TS  with the 
purified 25-1¢D  beparin-binding domain and coated this mix- 
ture. Even fewer spread cells were observed on this mixed 
surface than were seen on either the 70/50-kD fragment or 
the 25-kD domain alone (not shown). 
Fig. 5 shows the concentration dependence of cell attach- 
ment to the purified 70/50-kD trimer. A number of potential 
inhibitors of  cell binding to the 70/50-10) trimer were tested. 
The panel of mAbs was tested with the result that only A4.1 
and A6.1 inhibited cell attachment (Fig. 6). As expected, cell 
attachment to the beparin-binding domain (25 kD) was in- 
hibited by heparin, fucoidin, and dextran sulfates of mol wts 
5,000,  40,000,  and  500,000  (not  shown)  (Roberts  et  al., 
1987). Binding of  cells to the 70/50-kD trimers was also par- 
tially inhibited by heparin, heparan sulfate, fucoidin, and a 
panel of dextran sulfates of different molecular weights (Fig. 
7).  The order of potency found here is similar to that re- 
ported recently by Holt et al.  (1990)  for the competition 
of  binding of the homologous proteins properdin and antista- 
sin to immobilized sulfatides.  While the heparin and sul- 
Cell Attachment to Fragments of TS  o  loo 
To determine if the effect of mAb A4.1  on cell attachment  o°  80 
is because of its direct blocking of an adhesive site on TS or 
a conformational effect transmitted to one of the other do-  o 
mains of'IS, we prepared the fragment of'IS which contains  ~  60 
the epitope for A4.1  and tested its ability to  support cell  ~  40 
attachment.  We compared the ability of G361 cells to ad- 
here  to  wells  coated  with  intact  TS,  the  unfractionated  g 
chymotryptic digest,  the  purified  NH~-terminal  heparin-  ~  20 
binding domain and the 70/50-kD trimer.  To ensure com- 
plete digestion  we  used  vigorous  conditions  that  convert  o  0 
some of the 70- to the 50-kD fragment, both of which bind 
A4.1 (above). The unfractionated digest had 30--40%  (3 ex- 
periments) the attachment activity of undigested TS when 
coated at  equal  concentrations.  The  purified 25  kD  had 
10-20%  the  activity of "IS  while  the  purified 70/50  kD 
trimer had nearly the same activity as the digest, i.e., '~30% 
that of intact TS. These differences may be in part because 
of differences in the efficiency of coating of the different "IS 
fragments. Even so, the levels of attachment to the purified 
70/50 kD are quite significant and clearly indicate that ama- 
-  .t 
L  I  I  I  ]  0  2'0  4'0  6~0  8'0  '  L  lOO 
[Nab]  (/~g/ml) 
Figure 3. Inhibition by mAbs of G361 cell attachment to TS. Cells 
were incubated for 1 h at 37°C in wells coated with 50/tg/ml TS. 
Attachment was quantitated with a colorimetric, endogenous cellu- 
lax phosphatase assay (see Materials and Methods). Control wells 
had an absorbance at 410 between 1 and 1.5 in five separate experi- 
ments. Wells coated with BSA were used as negative controls and 
these values were routinely less than 1% of the positive controls. 
The mAbs were added to cells at the indicated concentrations: mAb 
A2.5 (o); mAb A6.1 (a); mAb C6.7 (m); mAb A4.1 (e). 
The Journal of Cell Biology,  Volume 112, 1991  1034 Figure 4.  Attachment of (3361 cells to TS fragments and peptides.  Wells were coated with 100 #g/ml ofTS: (A) 70•50  kD; (B) 25 kD; 
(C) or 100 #M of Peptide III (D), for 2 h at 37°C. After blocking with BSA, cells were allowed to attach for 90 min and photographed 
with a Hoffman 40x  objective.  Bar, 50 #m. 
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l~gure 5. Attachment of G361 cells to the 70/50 fragment of TS. 
The purified 70/50 kD was coated at indicated concentrations. The 
assay was performed as described and results expressed as percent 
maximum adherence to 10/zg/ml TS. 
fatide-binding activity of TS has been previously ascribed 
to  the  NH2-terminal  25-kD  domain  of TS  (Dixit  et  al., 
1984; Roberts et al., 1985), it seems that the 70-kD fragment 
of TS, and specifically the properdin-like type I repeats, may 
contain another binding site for these compounds. In fact, 
two of the type I repeats of TS contain the BBXB (where B 
is a basic amino acid) consensus glycosaminoglycan-bind- 
ing sequence identified in a number of heparin-binding pro- 
teins (Cardin and Weintraub, 1989). The effects of these sul- 
fated glycoconjugates on cell attachment to the 70/50-kD 
region of TS serves to focus attention on the properdin-like 
type I repeats of TS as potential cell-binding sites. 
Cell Attachment to Peptides 
To investigate this idea, we synthesized peptides based on the 
loo 
80 
40 
20 
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EMAb] (.glml) 
Figure 6. Effect  of  mAbs on attachment of  G361 cells  to the 701 
50-kD fragment.  In the standard assay mAbs were included at 
the indicated concentrations. The mAbs are: A2.5 (&); C6.7 (,,); 
A6.1 (o); A4.1 (e). Control attachment (100%) is that with no 
added mAb. 
core homology of the three properdin-like type I repeats of 
TS with properdin and the CS proteins. The sequences of  the 
three segments of TS are shown compared with the homolo- 
gous regions of properdin (Goundis and Reid,  1988), an- 
tistasin (Nutt et al.,  1988), and a CS protein in Fig. 8. The 
TS peptides were synthesized with alanines  replacing the 
cysteines, and peptide II was also synthesized with the cys- 
teines intact. 
We first tested these three peptides along with GRGDSP 
and its control, GRGESP as potential inhibitors of cell adhe- 
sion to "IS and 70/50-kD coated wells. GRGDSP at 1.5 mM 
inhibited  attachment of G361  cells to intact TS by 25% 
(+4%) while GRGESP was inactive (not shown). However, 
GRGDSP was completely inactive against attachment to the 
70/50-kD trimers as  expected since there is  no RGD se- 
quence within the 70-kD region of'IS. The three type I pep- 
tides caused a stimulation of cell attachment to both TS and 
the 70/50-kD fragment. We suspected that this effect was be- 
cause of the peptides binding to the blocked wells. Thus, we 
coated the peptides directly on the plastic wells to test their 
activity as cell attachment factors. As shown in Fig. 9, pep- 
tides II and HI were very potent at attaching cells, while pep- 
tide I was nearly inactive. Restoring the two cysteines in the 
peptide 1I sequence caused about a twofold increase in cell 
attachment activity. Using radioiodinated peptides, we com- 
pared the binding of the four type I peptides to the plastic 
wells. Peptides II and III bound to the plastic to identical ex- 
tents and peptide II with cysteines bound 50% better, thus 
explaining the increased cell attachment (above). Peptide I 
which bound cells very poorly, was in fact adsorbed to wells 
more efficiently than peptides II and III. Cell attachment to 
the peptides was blocked by the  same  sulfated glycocon- 
jugates that inldbited attachment to the 70/50-kD trimers 
(Fig. 7), indicating that the peptides probably represent the 
cell attachment site expressed within the 70-kD region of 
TS. Interestingly, heparin and heparan sulfate are more po- 
tent against peptide HI-mediated cell attachment than pep- 
tide H-mediated attachment. This may reflect the presence 
of a complete BBXB glycosaminoglycan-binding sequence 
at the COOH-terminal end of peptide HI. 
We raised polyclonal antibodies (pAbs) against the cys- 
teine-contalning form of peptide II in rabbits. These pAbs 
reacted with peptides II and HI having essentially no reaction 
with  peptide I  in  ELISA assays  (not  shown).  The pAbs 
reacted with both the 50- and 70-kD  species on Western 
blots (Fig. 2) thus establishing that the 50-kD fragment of 
TS does in fact contain the properdin-like sequences.  On 
Western blots of unreduced SDS gels, the pAb stains the tri- 
meric species which migrate in the 150-200-kD size range 
(not shown). The effect of the pAb on cell attachment to pep- 
tides II and HI, the 70/50-kD trimer and intact "IS is shown 
in Fig.  10. As expected, the most potent effect is on cell at- 
tachment to peptide II. However, cell attachment to peptide 
HI, the 70/50-kD trimers and intact TS is also substantially 
inhibited (Fig. 10). G361 cells adhere quite avidly to platelet 
factor 4, and this attachment is unaffected even at the highest 
concentrations of the pAb (Fig.  10). 
Discussion 
The data presented here indicate that a previously undetected 
site on TS can function in the attachment of melanoma (and 
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Figure 7. Effect of sulfated glycans on G361 
cell attachment to 70/50-kD fragment and 
peptides.  70/50-kD  fragment  was  coated 
at 25  #g/ml  and the  assay performed as 
described.  Peptides  were  coated  at  100 
#M. The following  inhibitors were included 
with cells at 50 #g/m1: (O) no inhibitor; 
(HEP)  heparin;  (H.S.)  heparan  sulfate; 
(FUC) fucoidin; (DEX-S) dextran sulfate, 
Mr  5,000; (DEX-M) dextran  sulfate, Mr 
40,000; (DEX-L)  dextran sulfate  Mr 500,000. 
probably other) cells to TS. This site is defined by the mAb 
A4.1, the 50-kD proteolytic fragment of'IS and is pinpointed 
by the activity of peptides II and III as cell attachment fac- 
tors. The inhibition of cell binding to the 70/50-kD fragment 
and intact "IS by mAb A4.1 and by the pAb against peptide 
II suggests that peptides II and HI are functional in the larger 
context of TS structure.  The biological importance of this 
site within TS is indicated by the fact that human melanoma 
G361 cells, human keratinocytes, squamous carcinoma cells 
(Varani  et al.,  1988),  and rat aortic smooth muscle cells 
(Majack et al., 1988) all adhere to "IS in a manner inhibited 
by mAb A4.1. In agreement with earlier results with larger 
fragments  of TS  (Roberts et al.,  1987),  we find that the 
70/50-kD fragment of TS does not support spreading of  these 
cells. 
An interesting and significant facet of the type I peptide 
sequences is their remarkable degree of conservation in a 
number of other proteins. As shown in Fig. 8, the three "IS 
peptides are most closely related to two classes of proteins 
synthesized by different stages  of Plasmodia  species,  the 
causative agent in malaria. The CS proteins are of particular 
interest in that they are thought to mediate binding of the 
sporozoites to liver, the first stage in the cycle of infection. 
In particular, region II of the CS protein, which is contained 
within the sequence shown in Fig.  8, is thought to be part 
of the recognition site.  Support for this idea comes from re- 
cent work of Rich et al. (1990) who found that a peptide se- 
quence in region II of th  9 Plasmodia  vivax CS protein is an 
attachment factor for T lymphocytic and myeloid cell lines. 
These authors used shorter peptides to narrow down the rec- 
ognition site to the sequence VTCG of region II. Interest- 
ingly, TS type I peptides II and HI contain this sequence and 
both are active in melanoma cell attachment, while peptide 
I does not contain this sequence (Fig.  8) and is not active 
(Fig. 9). This raises the possibility that the same receptor is 
present on G361 cells, the cell lines identified by Rich et al. 
(1990), and perhaps hepatocytes as well. If this is indeed the 
case, our data suggest that the cysteine is not a required de- 
terminant of this site since our peptides contain alanine at 
these positions. In fact Rich et al. (1990) remarked that the 
oxidation state of the Cys is not critical, suggesting that the 
recognition sequence is  probably VTXG.  The VTCG se- 
Peptides  I, II, III of Thrombospondin  and Related  Sequences 
Protein  Sequence  Residues 
Thrombospondin 
I  ~S  C~S T  SICG  N G  I  Q,QF'fflGI~  368-86 
II  V  T  C GEDIGrVTTIRTRI  424-42 
III  ISIPIWl o  Z lC  s  v  T  c  GIGIGIvlS-]K  R[EF~_E  I  461-99 
P. falciparum 
C.S. Protein 
TRAP 
Properdin  1 
2 
Antistasin  1 
2 
DI'~--~PIC  S  V  T  C  G  N  G  Z  QIVIRIRIRIRIRIRIRIRIRI~ 344-62 
TIE w sIPIc s  v  T  C G GI'K--'~I"T-"R-S  RLRIK~]  245-63 
I  G PlWJG  P  S  V  T  C  S  K  T  I  Q  116-34 
R  I  D  !  NICIR  KIT  CIPIN  G I  63-100 
Figure 8. Peptides used in this study and their 
homologues. The most highly conserved re- 
gions of the three TS type I repeats were se- 
lected for peptide synthesis. The sequences of 
these three peptides as they occur in TS (along 
with residue number in the TS sequence) are 
aligned in the first three lines.  The peptides 
used for most cell-binding studies contained al- 
anine residues in place of the two cysteines. 
Related amino acid sequences found in four 
other proteins are shown below their TS homo- 
logues. The cireumsporozoite protein (CSpro- 
tein) and the TRAP contain regions displaying 
the highest similarity to the 'IS repeats. The 
first two of six type I repeats of properdin are 
shown along with the two type I units of  antista- 
sin (see text for references to the sequences). 
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Figure 9. Attachment of G361 cells to synthetic TS peptides. Pep- 
tides I, 11, and m  of "IS (see Fig. 8) were coated on plastic wells 
at the indicated concentrations and the assay was performed as de- 
scribed. Peptide I (o); peptide II (zx); peptide m  (e). In this case, 
the actual absorbance at 410 nm is plotted. The value for intact TS 
(10 ~g/ml) in this experiment was 1.9 +  0.03. 
0  100  300  500  1000 
Pab(  gg/ml  ) 
Figure 10.  Effect  of antipeptide pAb on attachment of G361 cells 
to "IS, TS fragments, and peptides. Wells were coated with TS (-) 
at 10 gg/ml, 70/50 kD (e) at 25/A/ml;  or platelet factor 4 (t3) 
at 25/zg/ml. Peptide II (o) and peptide I17 (A) were coated at 100 
/zM. Assays were performed as described with pAb added to cells 
at the indicated concentrations. 
quence also occurs in TRAP (Robson et al., 1988) which is 
expressed on the surface of  parasitized erythrocytes at a later 
stage of infection. 
Our finding that sulfated glycoconjugates inhibit cell at- 
tachment to the type I peptides, particularly peptide HI, may 
indicate that a two domain-binding site is represented on 
these peptides. VTCG could represent a recognition site for 
a receptor and the BBXB sequence downstream would be a 
likely candidate for the glycoconjugate-binding site.  This 
would be particularly relevant if the receptor contained a 
glycosaminoglycan  chain in proximity to the VTCG-binding 
site. In this regard, it should be noted that all of the species 
of CS proteins and TRAP contain a  cluster of positively 
charged amino acids downstream of  the VTCG site and some 
contain a BBXB motif. Our preliminary data suggests that 
even though sulfated glycans inhibit cell attachment to the 
peptides, treatments of cells which reduce the numbers of 
glycosaminoglycan chains on their surface do not cause re- 
duced attachment. Cells grown in/3-D-xyloside (Hamati et 
al.,  1989)  or treated with heparitinase (Sun et al.,  1989), 
show no deficit in their attachment to peptides II and m 
(Prater, C. A., and W. A. Frazier, unpublished data). This 
suggests  that cell surface glycosaminoglycans are not the 
receptor for the peptides, but does not rule out their involve- 
ment as a modulator of reeeptor-peptide interactions. 
Homologues of the type I repeats of "IS are also found in 
the human protein properdin  (Goundis and Reid,  1988). 
This protein consists of little else besides six copies of the 
TS type I motif. Properdin is thought to stabilize complex 
formation between factors C3b and the protease Bb of the 
complement system leading to the formation of the conver- 
tase which activates C3 and C5.  Goundis and Reid (1988) 
who sequenced properdin eDNA and noted the homology 
between TS  and the complement proteins C6 through C9 
(Haefliger et al.,  1989),  speculated that the type I repeats 
may be involved in a membrane-binding event. This could 
occur directly to a unique receptor for type I motifs or in- 
directly by first binding to C3b (or its derivatives) which 
would then bind to CR1, CR2, or CR3. We have tried to de- 
tect the binding of radioiodinated TS to C3b immobilized 
on plastic wells and found no specific interaction (Prater, 
C. A., and W. A. Frazier, unpublished data). Thus it seems 
likely that some direct interaction may occur between the 
type I repeats of TS (and perhaps its homologues) and a re- 
ceptor on the surface of G361 cells, liver, and some circulat- 
ing cells (Rich et al.,  1990). 
Another protein that contains more distantly related TS 
type I repeats is the leech protein antistasin, so named for 
its anticoagulant properties (Nutt et al.,  1988).  Holt et al. 
(1990) have recently shown that TS, properdin, and antista- 
sin all bind to sulfatide [Gal(3-SO0fll-lCer], and this bind- 
ing has a very similar profile of inhibition by sulfated glyco- 
conjugates for all three proteins. Since the only homologous 
sequence among these three proteins is their TS type I repeat 
structures, Holt et al. (1990) suggest that this sequence forms 
the binding site for sulfatides and glycosaminoglycans.  These 
observations along with our data suggest that TS has a sec- 
ond "sulfated  glycan binding" domain distinct from the previ- 
ously characterized NH2-terminal  25-kD  heparin-binding 
domain. It should be noted that antistasin type I repeats do 
not contain the VTCG sequence found in "IS, properdin, and 
the CS proteins (Fig. 8). 
Other  adhesive glycoproteins have multiple heparin  or 
glycosaminoglycan  binding domains. For example, fibronec- 
tin has at least two well-characterized heparin-binding sites, 
one active at physiological salt concentrations and another 
site  which  is  effective  at binding  heparin  at  lower ionic 
strength (Ruoslahti,  1988).  However,  this second site may 
have higher affinity for another glycosaminoglycan or sul- 
fatide. Laminln has three characterized heparin-binding re- 
gions, two in the B chain and one in the A chain, each of 
which  has  been  modeled as  a  peptide  sequence  (Kouzi- 
Koliakos et al., 1989). Type IV collagen has also been found 
to display three distinct affinities for heparin (Tsilibary et al., 
1988) corresponding to three sites distributed at three dis- 
tinct locations along the type IV molecule. Thus it appears 
that multiple heparin-binding sites are commonly present in 
extracellular adhesive glyeoproteins. While heparin affects 
the assembly of laminin polymers (Kouzi-Koliakos et al., 
1989) and type IV collagen polymers (Tsilibary et al., 1988), 
little is known about the functions of these binding sites in 
vivo,  or even the precise nature of their physiological li- 
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an artificial probe that is conveniently available,  and is prob- 
ably not the relevant  ligand in vivo. 
Two other regions at which ceils attach  to "IS are found 
near the COOH terminus of the peptide chain. These are the 
RGDA  sequence  at  the  COOH  terminus  of the calcium- 
binding domain and the COOH-terminal "ten-binding ~ do- 
main. The receptor for the RGDA site appears to be related 
or identical to the vitronectin receptor, a ~3 integrin (Law- 
ler et al.,  1988). It is likely that the exposure or conforma- 
tion of the RGD sequence is regulated by calcium (Frazier, 
1987;  Lawler et al., 1988).  The identity of the receptor for 
the COOH-terminal cell-binding domain of TS is somewhat 
controversial. Asch et al. (1987) have reported that platelet 
glycoprotein IV (or IIIb) is the TS receptor, and that this pro- 
tein is the same as the antigen CD36 defined by mAb OKM5. 
However, expression of CD36 does not lead to TS binding 
while another function ascribed to CD36,  i.e.,  binding of 
malaria-parasitized  red ceils,  is present  (Oquendo  et  al., 
1989).  It is this COOH-terminal domain of "IS with which 
mAb C6.7 reacts to block adhesion of a number of cell types 
to TS-coated surfaces and to inhibit secondary phase (secre- 
tion dependent) platelet aggregation  (Dixit et al.,  1985b). 
The fact that mAb A4.1 does not affect platelet aggregation 
is consistent with a separate cell-binding site in the TS type 
I repeats whose receptor is not present on platelets. 
The  functional  consequences  of cellular  interaction  at 
these four sites on TS remain to be elucidated. One can spec- 
ulate that the different receptors that bind to these sites are 
linked to different signal transduction mechanisms or per- 
haps  to  different  eytoskeletal  proteins.  Taraboletti  et  al. 
(1987) reported that the amino terminal heparin-binding do- 
main of TS is required for melanoma cell spreading while the 
COOH-terminal cell-binding domain is necessary for their 
attachment, but will not allow spreading  to occur. This sug- 
gests a differential interaction of these TS domains with the 
eytoskeletal apparatus. Furthermore, TS appears to have op- 
posite effects on cellular proliferation in different ceil types. 
Rat aortic smooth muscle ceils respond to PDGF treatment 
by making and secreting TS very rapidly, and this extraceilu- 
lar "IS seems to be permissive or stimulatory for cell divi- 
sion in response to the mitogen (Majack et al., 1985,  1988). 
Bovine capillary endothelial cells chemotax toward  bFGF 
which is also a mitogen for these ceils and a potent angio- 
genic stimulus in vivo (Rastinejad et al., 1989; Folkman and 
Klagsbrun,  1987). "IS blocks the migration and proliferation 
of BCEC in response to bFGF in vitro (Good et al.,  1990; 
Taraboletti et al., 1990).  These effects would appear to ac- 
count for the finding that "IS is a potent inhibitor of angiogen- 
esis in three in vivo assays (Good et al., 1990). These oppo- 
site effects of TS on smooth muscle cells and bovine capillary 
endothelial cells may reflect the presence of different sets of 
TS receptors on these ceil types that recognize different sites 
on TS. The situation  may be even more complex. We have 
recently found that an isoform of'IS exists that is derived by 
alternative  splicing of "IS mRNA to yield a protein that con- 
talns the NH2-terminal  heparin-binding  domain of "IS but 
none of the other three cell attachment  sites  (Paul et al., 
1990). Preliminary evidence suggests that other "IS isoforms 
exist that may lack other ceil attachment  sites thus setting the 
stage for a complex set of protein variants which can interact 
with as many as four cellular receptors. 
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